Development and Validation of an LC-MS/MS Method for Quantitative Determination of Alprazolam in Human Plasma: A Bioequivalence Study
Keywords:
Alprazolam , LC-MS/MS , Bioequivalence, Plasma quantificationAbstract
This study details the development and validation of a highly sensitive LC-MS/MS method for the quantification of Alprazolam in human plasma. The analytical procedure adhered to guidelines provided by regulatory authorities, including EMEA and ICH M10, ensuring comprehensive validation across parameters such as specificity, accuracy, precision, carry-over, linearity, matrix effect, and stability. The method employs a Quattro Micro quadrupole mass spectrometer with an electrospray ionization (ESI) source in positive mode, coupled with an Agilent Zorbax SB-C18 column. Alprazolam and an internal standard, Lorazepam, were monitored using multiple reaction monitoring (MRM) with transitions of 308.90→281.00 and 320.80→275.00, respectively.
Calibration curves were linear over a concentration range of 0.5–16 ppb (R² > 0.99). The lower limit of quantification (LLOQ) was determined to be 0.5 ppb, meeting the acceptance criteria for signal-to-noise ratio (S/N > 10). Validation results demonstrated intra- and inter-day precision with RSD ≤ 6.8% and accuracy deviations ≤ 6.1%. Matrix effects, evaluated using plasma samples from six individuals, showed mean deviation factors within acceptable limits (<15%). Short-term, freeze-thaw, and long-term stability studies confirmed the robustness of the analyte under various conditions. Application of the validated method to a bioequivalence study involved plasma sample analysis from healthy volunteers after administration of test and reference formulations. Pharmacokinetic parameters such as Cmax, Tmax, and AUC were computed, confirming bioequivalence based on predefined regulatory criteria.
This validated LC-MS/MS method offers high precision, reliability, and sensitivity, making it suitable for bioequivalence studies and therapeutic drug monitoring of Alprazolam.
Downloads
References
1. Kumar, Sandeep, and Singh, Nidhi. (2021). Advancements in bioanalytical techniques for quantifying antibiotics in human plasma: Application of LC-MS/MS. Bioanalysis. 13(5), 301-319.
2. Villar-López, Ana. (2022). Automation in LC-MS/MS workflows: Enhancing efficiency and accuracy in pharmacokinetics studies. Trends in Analytical Chemistry. 45(3), 185-197.
3. Hazen, Benjamin et al. (2021). LC-MS/MS methods for therapeutic drug monitoring: Focus on anti-epileptic drugs. Clinical Biochemistry. 54(7), 553-562.
4. Shimadzu Corporation. (2020). Optimizing sensitivity in LC-MS/MS for low-volume plasma analysis. Shimadzu White Papers. Retrieved from shimadzu.com.
5. Alturas Analytics. (2022). Development of LC-MS/MS methodologies for bioequivalence studies of benzodiazepines. Analytical Perspectives. 10(1), 55-70.
6. Chandra, Ravi. (2014). Techniques for minimizing matrix effects in LC-MS/MS quantification. Bioanalytical Methods. 5(12), 1234-1245.
7. Accessdata. (2020). Guidelines for bioequivalence studies using LC-MS/MS. U.S. FDA. Retrieved from accessdata.fda.gov.
8. PubMed. (2023). Comparative review of LC-MS/MS methods in pharmacokinetics. Pharmaceutical Sciences Journal. Retrieved from pubmed.ncbi.nlm.nih.gov.
9. ICH M10. (2019). Bioanalytical Method Validation. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
10. EMEA. (2012). Guidelines on bioanalytical method validation. European Medicines Agency.
